<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496870</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-OPC-1706</org_study_id>
    <nct_id>NCT03496870</nct_id>
  </id_info>
  <brief_title>A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.</brief_title>
  <official_title>A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open-label study to assess the pharmacokinetics, pharmacodynamics, safety,
      and tolerability of opicapone when administered orally once daily for 14 days as adjunctive
      therapy to carbidopa/levodopa in subjects with Parkinson's disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic evaluation of opicapone and its metabolites: area under the curve (AUC 0-24)</measure>
    <time_frame>up to 19 days</time_frame>
    <description>Area under the plasma concentration versus time curve from 0 to 24 hours for analytes with quantifiable concentrations at 24 hours postdose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic evaluation of opicapone and its metabolites: area under the curve (AUC 0-tlast)</measure>
    <time_frame>up to 19 days</time_frame>
    <description>Area under the plasma concentration versus time curve from 0 hour to the time of the last measurable concentration for analytes below the limit of quantification at 24 hours postdose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic evaluation of opicapone and its metabolites: Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to 19 days</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic evaluation of opicapone and its metabolites: Time to maximum plasma concentration (tmax)</measure>
    <time_frame>up to 19 days</time_frame>
    <description>Time to maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic evaluation of levodopa following administration of opicapone: area under the curve (AUC 0-tlast)</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Area under the plasma concentration versus time curve from 0 hours to time before next levodopa dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic evaluation of levodopa following administration of opicapone: maximum plasma concentration (cmax)</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (safety and tolerability)</measure>
    <time_frame>up to 19 days</time_frame>
    <description>Number of participants with reported adverse events after study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic evaluation of opicapone on S-COMT activity</measure>
    <time_frame>up to 19 days</time_frame>
    <description>Maximum inhibition of S-COMT activity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Opicapone once daily with Carbidopa/Levodopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Opicapone administered once daily for 14 days; carbidopa/levodopa administered at set frequency on Study Days 1, 2 &amp; 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opicapone</intervention_name>
    <description>catechol-O-methyltransferase (COMT) inhibitor</description>
    <arm_group_label>Opicapone once daily with Carbidopa/Levodopa</arm_group_label>
    <other_name>BIA 9-1067</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa Levodopa</intervention_name>
    <description>Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor</description>
    <arm_group_label>Opicapone once daily with Carbidopa/Levodopa</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a clinical diagnosis of idiopathic Parkinson's Disease (PD) for at least 3 years
             with clear improvement with levodopa treatment

          2. Be at a stable dose of maintenance medication(s) for PD, including stable doses of
             CD/LD

          3. Subjects of childbearing potential who do not practice total abstinence must agree to
             use hormonal or two forms of nonhormonal contraception (dual contraception)
             consistently during the screening, treatment and follow-up periods of the study

          4. Have a body mass index (BMI) of 18 to 40 kg/m2

          5. Have a modified Hoehn and Yahr stage of â‰¤4 in the OFF state

          6. Be able to tolerate an overnight period of 12 hours without CD/LD

          7. Be in good general health and expected to complete the clinical study as designed

        Exclusion Criteria:

          1. Are currently pregnant or breastfeeding

          2. More than 2 alcoholic beverages daily or more than 14 alcoholic beverages weekly
             within 7 days of Day -1 or consume any alcohol within 48 hours of Day -1.

          3. Have motor fluctuations during the day (ie, effect of levodopa &quot;wearing off&quot; or having
             unpredictable &quot;off&quot; periods), or severe or intolerable levodopa-induced dyskinesia

          4. Have had previous exposure to opicapone, or have an allergy, hypersensitivity, or
             intolerance to opicapone or other COMT inhibitor.

          5. Have a history of a medical condition or surgical procedure that might interfere with
             absorption or metabolism.

          6. Have a known history of neuroleptic malignant syndrome

          7. Have an unstable medical condition or chronic disease

          8. Have taken certain prohibited medications within 28 days of Day -1.

          9. Have a known or suspected diagnosis of AIDS, or have tested seropositive for HIV

         10. Have hepatitis A or B

         11. Have a significant risk of suicidal or violent behavior
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Chen</last_name>
    <phone>858-617-7744</phone>
    <email>cechen@neurocrine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

